$30 Billion Drug Deal

Image source: Vecster - Shutterstock

What's going on?

Biotech giant Amgen announced on Monday that its buying drugmaker Horizon Therapeutics in a deal worth almost $30 billion.

What does this mean?

Amgen just made a big move. The firm announced its buying Horizon for a staggering $26 billion, its biggest-ever deal, in a splurge that comes hot on the heels of the near $4 billion acquisition of ChemoCentryx earlier this year. No wonder its making moves: stiff competition and an upcoming patent expiry have hit Amgens top-selling arthritis drug for four straight quarters, and this acquisition will help the firm replenish its offerings with a crop of popular approved drugs. Case in point: the deal will see Amgen bulk up its portfolio with the eye disease treatment Tepezza, a drug thats already a tidy money-maker.

Why should I care?

Zooming in: Pharma feeding time.
Horizons shares were down 27% earlier this year, which is probably a key reason that other pharma companies, including Sanofi and Johnson & Johnson, started sizing the firm up in the first place. No surprise: the biotech sector entered its biggest selloff since the early 2000s this year, and that led analysts to predict that drugmakers with deep pockets would snap up rivals and replenish their product pipelines. And they weren’t far off: other standout deals include Johnson & Johnson’s $17 billion acquisition of Abiomed last month and Pfizer’s $12 billion purchase of Biohaven Pharmaceuticals in May.

The bigger picture: Festive shopping spree.
This weeks been a busy one for dealmakers, with firms rushing to get contracts signed and initialed before the holiday season kicks into gear. So far, Thoma Bravos announced an $8 billion takeover of spending-management platform Coupa, Novozymes has said its buying fellow enzyme-maker Chr. Hansen for around $12 billion, and Microsofts bitten off a $2 billion chunk of the London Stock Exchange. Thats a fat $70 billion in deals this week alone not bad considering overall dealmakings down by a third this year (tweet this).

Originally posted as part of the Finimize daily email.

The top 2 financial news stories in 3 minutes. Join over one million Finimizers

Read next

No Fall In Fall After All

Sign up to Finimize

Get the two most important global financial news stories each day. Sent at midnight UK time.

Get started with one email a day

The top financial news stories in 3 minutes.